Director Douglas Joseph Hirsch filed a Form 4 with the SEC on October 26, 2026, reporting the vesting and conversion of 20,521 restricted stock units into Class A Common Stock of GoodRx Holdings, Inc. (NASDAQ:GDRX).

Key Highlights

  • Transaction: 20,521 restricted stock units converted to Class A Common Stock on October 26, 2026, via transaction code M, at a derivative security price of $0.
  • Direct ownership after transaction: 341,457 shares of Class A Common Stock held directly by Hirsch following the reported transaction.
  • Indirect holdings: Hirsch also reports indirect beneficial ownership of 543,377 shares via DH 2024-2 GRAT and 2,089,343 shares via DH 2025 GRAT, both of which he serves as sole trustee and sole annuitant.
  • Spouse-linked trusts disclosed but disclaimed: 543,377 shares held by CH 2024-2 GRAT and 2,089,343 shares held by CH 2025 GRAT are reported, with Hirsch disclaiming beneficial ownership of both.
  • Vesting schedule: The RSU award vests in one-third increments on each of the first three anniversaries of the grant date, beginning October 26, 2025, subject to continued service.
  • Remaining RSUs: 20,521 restricted stock units remain beneficially owned directly following the transaction.

Hirsch RSU Conversion and Beneficial Ownership Details at GoodRx

According to the filing, Douglas Joseph Hirsch, a director of GoodRx Holdings, Inc., reported a transaction on October 26, 2026, in which 20,521 restricted stock units were converted into shares of Class A Common Stock. The filing notes that each restricted stock unit represents a contingent right to receive one share of Class A Common Stock. The transaction code is listed as M, and the price of the derivative security is stated as $0. Following the transaction, Hirsch directly holds 341,457 shares of Class A Common Stock.

The filing also discloses indirect holdings through two grantor retained annuity trusts for which Hirsch serves as sole trustee and sole annuitant: the DH 2024-2 GRAT, holding 543,377 shares, and the DH 2025 GRAT, holding 2,089,343 shares. Additionally, 1 share is reported as indirectly held by Hirsch's spouse. Two further trusts, the CH 2024-2 GRAT and the CH 2025 GRAT, each holding 543,377 and 2,089,343 shares respectively, are disclosed as controlled by Chona Hirsch, the reporting person's spouse. The filing states that Hirsch "has no pecuniary interest in or voting or investment control over" those shares and disclaims beneficial ownership of them, adding that "this filing is not an admission or acknowledgment that the Reporting Person is the beneficial owner of such shares."

The RSU award underlying the reported transaction vests as to one-third of the shares on each of the first three anniversaries of the grant date, beginning October 26, 2025, subject to continued service through each applicable vesting date, according to the filing. The Form 4 was signed by Gracye Cheng as Attorney-in-Fact for Douglas Joseph Hirsch on October 26, 2026.

What Was Disclosed

Director Douglas Joseph Hirsch reported the vesting of 20,521 restricted stock units into GoodRx Holdings Class A Common Stock on October 26, 2026, along with direct and indirect beneficial ownership across multiple grantor retained annuity trusts, with disclaimers on spouse-controlled trusts.